New hope for tough cancers: veonetinib trial launches
Disease control
Recruiting now
This Phase 2 trial tests an oral drug called veonetinib (AL8326) in 80 adults with advanced small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma who have already tried at least one prior treatment. The study aims to find the best dose and see if the drug ca…
Phase: PHASE2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC